产品说明

一般描述

A cell-permeable benzothiazepine derivative of clonazepam that acts as a specific and potent inhibitor of the mitochondrial Na⁺/Ca²⁺ exchanger (IC₅₀ = 360 nM). Enhances the export of Ca²⁺ from isolated mitochondria. Also reported to directly inhibit voltage-gated Ca²⁺ channels.

包装

5 mg in Plastic ampoule
Packaged under inert gas

生化/生理作用

Cell permeable: yes
Target IC₅₀: 360 nM against mitochondrial Na+/Ca2+ exchanger
Product does not compete with ATP.
Reversible: no
Primary Target
Mitochondrial Na+/Ca2+ exchanger

警告

Toxicity: Standard Handling (A)

制备说明

Dilute in Ca²⁺-free buffer just prior to use.

重悬

Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

其他说明

Jornot, L., et al. 1999. J. Cell Sci.112, 1013.
Babcock, D.F., et al. 1997. J. Cell Biol.136, 833.
Baron. K.T., and Thayer, S.A. 1997. Eur. J. Pharmacol.340, 295.
Griffiths, E.J., et al. 1997. Cell Calcium21, 321.
White, R.J., and Reynolds, I.J. 1996, J. Neurosci.16, 5688.
Cox, D.A., et al. 1993. J. Cardivasc. Pharmacol.21, 595.
Cox, D.A., and Matlib, M.A. 1993. J. Biol. Chem.268, 938.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

基本信息

产品性质

安全信息

产品说明

一般描述

CGP-37157 是苯并噻氮平化合物，衍生自氯硝西泮。它可作为肌浆网/内质网 Ca²⁺ ATPase(SERCA)拮抗剂和兰尼碱受体通道(RyR)激动剂。CGP-37157 调节平滑肌、心脏和骨骼肌细胞以及非肌肉系统中钙的胞内信号传导。

应用

CGP-37157 作为线粒体钠钙交换剂(mNCX)抑制剂，用于研究正常线粒体钙动力学在维持树突棘生成中的作用。

包装

5, 25 mg in glass bottle

生化/生理作用

线粒体 Na⁺/Ca²⁺ 交换以及肌质网钙刺激的 ATPase 和其他钙通道的特异性抑制剂。

基本信息

产品性质

安全信息

基本信息